Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours
December 3, 2024
December 3, 2024
November 27, 2024
November 19, 2024
November 18, 2024
November 14, 2024
November 8, 2024
October 28, 2024
October 9, 2024
October 8, 2024
January 9, 2026
Cycle Pharmaceuticals Ltd (Cycle) and Inceptua Group (Inceptua) have announced the expansion of their partnership to make NITYR® (nitisinone) tablets ...
December 4, 2025
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that c...
October 30, 2025
Lonza to acquire Redberry SAS, an innovative company specializing in rapid microbiology testing solutions Acquisition to include Red One™ solid-phase ...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225